Clinical Trial Update: Regulatory Post-Marketing Surveillance Study for Brolucizumab

View source ↗

Summary

Regulatory post-marketing surveillance clinical trial for brolucizumab is recruiting to monitor safety in neovascular age-related macular degeneration.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• BEOVU (BROLUCIZUMAB)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Neovascular Age-related Macular Degeneration | Status: RECRUITING